Arcturus Therapeutics Holdings Inc. ARCT R2K
Healthcare · Biotechnology · United States
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
READ MORE ›$7.92
-36.79% 1Y
Market & Price
Market Cap
$225.11M
Current Price
$7.92
High / Low (52W)
$23.16 / $5.90
Beta
2.42
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$6.73
Price to Book
1.18
P/S
4.11
EV/EBITDA
-0.44
Dividend Yield
-
Profitability & Returns
ROCE
-28.02%
ROE
-37.01%
ROA
-19.14%
Profit Margin
-
Op Margin
-
EPS (Latest Qtr)
$-0.95
EPS (TTM)
$-2.83
Balance Sheet & Liquidity
Debt/Equity
0.13
Quick Ratio
6.19
Current Ratio
6.31
Debt
$23.99M
Total Assets
$271.15M
Current Assets
$241.45M
Working Capital
$205.07M
Ownership
Promoter Holding
7.99%
Chg in Prom Hold
0.00%
FII / Inst Holding
80.26%
Chg in FII Hold
-0.00%
Financial Snapshot
Enterprise Value
$37.72M
Total Revenue (TTM)
$54.71M
EBITDA
$-85.48M
Free Cash Flow
$11.29M
Operating Cash Flow
$-58.57M
Shares Outstanding
28.42M
Gross Margin
-80.67%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
-31.13%
Profit 5Y
-267.88%
Revenue (YoY)
-93.00%
Earnings (YoY)
-
PROS
- Generates positive free cash flow.
CONS
- Revenue declined at -31.1% CAGR over 5 years.
- Earnings shrank at -267.9% CAGR over 5 years.
- Trading 65.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ARCT Arcturus Therapeutics Holdings Inc. R2K | 7.92 | - | $225.11M | - | -28.02% | -37.01% | -31.13% | -267.88% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.39M | 3.42M | 4.35M | 10.15M | 3.32M | 2.97M | 2.65M | 2.32M | 2.33M | 2.24M | 2.13M | 2.00M | 2.44M | 5.79M | 5.24M | 27.09M | 13.37M | 80.28M | 10.52M | 45.14M | 38.01M | 49.86M | - | - | 25.48M | 24.51M | 14.15M | 3.08M | 610.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 42.30M | 36.13M | 30.66M | 34.39M | 29.54M |
| Operating Income | -10.07M | -4.36M | -6.51M | -572.00K | -7.62M | -10.82M | -9.46M | -10.04M | -20.94M | -31.08M | -57.67M | -53.72M | -53.82M | -37.65M | -50.38M | -22.09M | -36.81M | 14.76M | -55.37M | -19.31M | -30.41M | -21.13M | - | - | -16.83M | -11.62M | -16.51M | -31.31M | -28.93M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -16.02M | -10.84M | -15.75M | -20.14M | -28.27M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -14.08M | -9.18M | -13.45M | -29.08M | -26.96M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -4.00K | 0 | 4.00K | 0 | -4.00K | - |
| Net Income | -9.95M | -4.25M | -6.88M | -685.00K | -7.43M | -10.99M | -9.78M | -10.26M | -21.00M | -31.10M | -56.35M | -54.58M | -54.08M | -38.66M | -51.17M | -21.56M | -35.27M | 50.75M | -52.55M | -16.22M | -26.82M | -17.22M | - | - | -14.08M | -9.18M | -13.45M | -29.08M | -26.96M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | -2.07 | -2.05 | - | -1.94 | -0.82 | -1.33 | 1.87 | -1.98 | -0.61 | -1.00 | -0.64 | - | - | -0.52 | -0.34 | -0.49 | -1.03 | -0.95 |
| R&D Expense | 4.22M | 3.97M | 7.32M | 7.27M | 7.05M | 11.99M | 7.92M | 7.94M | 17.70M | 24.29M | 50.05M | 45.68M | 45.40M | 32.63M | 44.89M | 38.19M | 37.69M | 51.77M | 52.67M | 51.08M | 53.57M | 58.67M | 39.13M | - | 34.89M | 29.58M | 23.27M | - | 21.53M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 15.75M | 20.79M | 9.54M | - | 205.75M | 157.75M | 138.39M | 67.22M |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | 193.58M | 235.95M | 234.06M | 143.48M |
| Operating Income | -21.81M | -25.51M | -71.52M | - | 12.18M | -78.20M | -95.67M | -76.26M |
| EBITDA | - | - | - | - | 13.70M | -24.16M | -77.40M | -62.75M |
| Interest Expense | - | - | - | - | 3.00M | 768.00K | 0 | 9.00K |
| Pretax Income | - | - | - | - | 10.64M | -27.89M | -80.94M | -65.78M |
| Tax Provision | - | - | - | - | 1.29M | 1.83M | -4.00K | 0 |
| Net Income | -21.79M | -25.99M | -72.15M | - | 9.35M | -29.73M | -80.94M | -65.78M |
| Diluted EPS | - | - | - | - | 0.35 | -1.00 | -3.00 | -2.40 |
| R&D Expense | 16.98M | 33.64M | 57.85M | 173.76M | 147.75M | 192.13M | 195.16M | 112.21M |
Compounded Sales Growth
| 5 Years: | -31.13% |
| 1 Year: | -93.00% |
Compounded Profit Growth
| 5 Years: | -267.88% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -36.79% |
| 6 Months: | +16.47% |
| 3 Months: | -3.77% |
| 1 Month: | -5.71% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 44.20M | 82.14M | 476.46M | - | 450.39M | 429.40M | 344.07M | 271.15M |
| Current Assets | - | - | - | - | - | 403.33M | 386.59M | 305.98M | 241.45M |
| Cash & Equivalents | - | 36.71M | 71.35M | 462.89M | - | 391.88M | 292.00M | 237.03M | 230.91M |
| Inventory | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | 2.76M | 32.06M | 3.97M | 5.56M |
| Total Liabilities | - | 30.56M | 56.35M | 79.90M | - | 180.07M | 150.89M | 103.09M | 57.16M |
| Current Liabilities | - | 12.58M | 21.32M | 49.52M | - | 126.98M | 81.99M | 65.49M | 36.38M |
| Long Term Debt | - | 9.91M | 14.99M | 13.85M | 40.63M | - | - | - | - |
| Total Debt | - | - | - | - | - | 94.75M | 30.22M | 28.55M | 25.00M |
| Total Equity | 33.79M | 13.64M | 25.79M | 396.55M | - | 270.31M | 278.51M | 240.98M | 213.99M |
| Shares Outstanding | - | - | - | - | - | 26.55M | 26.83M | 27.00M | 28.41M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -20.76M | -6.45M | -42.86M | - | 31.99M | -18.10M | -59.75M | -74.27M |
| Investing Cash Flow | 22.13M | -818.00K | -1.74M | - | -7.73M | -2.90M | -648.00K | -230.00K |
| Financing Cash Flow | 10.20M | 41.91M | 436.14M | - | -2.86M | -24.09M | 5.42M | 13.38M |
| Capital Expenditure | -1.48M | -818.00K | -1.74M | - | -7.73M | -2.90M | -648.00K | -230.00K |
| Free Cash Flow | -22.24M | -7.26M | -44.60M | - | 24.27M | -21.00M | -60.40M | -74.50M |
| Net Change in Cash | - | - | - | - | 21.41M | -45.09M | -54.98M | -61.12M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | -138.5% | -122.7% | -749.8% | - | 5.9% | -49.6% | -69.1% | -113.4% |
| Net Margin % | -138.3% | -125.0% | -756.3% | - | 4.5% | -18.8% | -58.5% | -97.9% |
| ROE % | -159.7% | -100.8% | -18.2% | - | 3.5% | -10.7% | -33.6% | -30.7% |
| ROCE % | -69.0% | -41.9% | -16.8% | - | 3.8% | -22.5% | -34.3% | -32.5% |
Shareholding Pattern
Insiders
7.99%
Institutions
80.26%
Public Float
87.23%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Federated Hermes, Inc. | 11.62% | 3.30M | $26.16M |
| 2 | ARK Investment Management, LLC | 9.74% | 2.77M | $21.93M |
| 3 | Blackrock Inc. | 9.19% | 2.61M | $20.70M |
| 4 | Sumitomo Mitsui Trust Group, Inc. | 8.05% | 2.29M | $18.13M |
| 5 | Amova Asset Management Americas Inc | 8.05% | 2.29M | $18.13M |
| 6 | Vanguard Capital Management LLC | 3.89% | 1.11M | $8.77M |
| 7 | Two Sigma Investments, LP | 3.81% | 1.08M | $8.57M |
| 8 | Vanguard Portfolio Management LLC | 3.44% | 977.92K | $7.75M |
| 9 | Geode Capital Management, LLC | 2.33% | 660.93K | $5.23M |
| 10 | State Street Corporation | 1.91% | 543.86K | $4.31M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ARCT
No recent headlines available.